valsartan · Novartis · NDA 020665, 021283
Diovan
Earliest generic entry, as listed · earliest of 4 marketed strengths
Open now
No unexpired patents or exclusivities are listed for this product.
Listed patents · 0 unexpired
No unexpired patents listed.
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
- Generic approved · ANDA 218897, Pharmobedient · 021283-001Approved 21 Apr 2026Detected 25 Oct 2026Historical import
- Generic approved · ANDA 205357, Bostal Drug · 021283-001Approved 11 Aug 2026Detected 25 Oct 2026Historical import
Products covered · 6
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 020665 · 001 · discontinued | capsule, oral | 80MG | open |
| 020665 · 002 · discontinued | capsule, oral | 160MG | open |
| 021283 · 001 · RLD | tablet, oral | 80MG | open |
| 021283 · 002 · RLD | tablet, oral | 160MG | open |
| 021283 · 003 · RLD | tablet, oral | 320MG | open |
| 021283 · 004 · RLD | tablet, oral | 40MG | open |